What to Trust, PSA or [ 68 Ga]Ga-PSMA-11: Learn from Experience.

Autor:	Viglialoro R; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Esposito E; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Zanca R; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Gessi M; Neuropathology Unit, Division of Pathology Fondazione Policlinico Universitario 'A.Gemelli' IRCCS, Università Cattolica del Sacro Cuore, Roma, Italy., Depalo T; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Aghakhanyan G; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Bartoli F; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy., Sollini M; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, 20090, Italy.; IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy., Erba PA; Regional Center of Nuclear Medicine, Department of Translational Research and New Technology in Medicine, University of Pisa, Pisa, Italy.; Azienda Ospedaliero Universitaria Pisana, Pisa, Italy.; Department of Nuclear Medicine and Molecular Imaging, Medical Imaging Centre, University Medical Center Groningen, Groningen, the Netherlands.
Jazyk:	angličtina
Zdroj:	Research and reports in urology [Res Rep Urol] 2021 Aug 20; Vol. 13, pp. 597-601. Date of Electronic Publication: 2021 Aug 20 (Print Publication: 2021).
DOI:	10.2147/RRU.S316446
Abstrakt:	Brain metastases from prostate cancer typically occur in the more advanced stages of the disease. Clinically, the early diagnosis of visceral disease is crucial, impacting on patient's management and prognosis. Although magnetic resonance imaging (MRI) is the modality of choice for the detection of brain metastases, it is not routinely performed in the surveillance of prostate cancer patients unless neurological manifestations appear. Prostate-specific membrane antigen (PSMA) is a glycoprotein, a membrane-bound metallopeptidase, overexpressed in more than 90% of prostate cancer cells. This molecular target is a suitable tissue biomarker for prostate cancer functional imaging. We present a case of a 73-year gentleman diagnosed with prostate adenocarcinoma and surgically treated (pT3bN1Mx, Gleason Score of 9) in February 2016. Subsequently, he underwent androgen deprivation therapy because of the occurrence of a bone metastasis. Between 2016 and January 2019 PSA levels were maintained under control. Starting from September 2019, it progressively raised up to 0.85 ng/mL with a doubling time of 3.3 months. Therefore, he performed a [ 68 Ga]Ga-PSMA-11 PET/CT which showed a focal radiopharmaceutical uptake in the right temporal lobe corresponding to the presence of a rounded cystic lesion on brain MRI. The subsequent excisional biopsy diagnosed a prostate adenocarcinoma metastasis. PSMA expression has been reported in brain parenchyma after ischemic strokes and in some brain tumors including gliomas, meningiomas, and neurofibromas. In our case, the lack of symptoms and the relatively low PSA level raised questions about the nature of the lesion, posing the differential diagnosis between brain metastases and primary brain tumor. Finally, our case shows the capability of [ 68 Ga]Ga-PSMA-11 PET/CT to detect metachronous distant brain metastases in a low biochemical recurrent asymptomatic prostate cancer patient, indicating that proper acquisition - from the vertex to thigh - should be always considered, regardless of the PSA level. Competing Interests: Prof. Dr. Paola Anna Erba report grants from AIRC, during the conduct of the study; grants from AAA, personal fees, non-financial support from GE, royalties from Springer, personal fees, non-financial support from Philogen outside the submitted work. The authors report no other conflicts of interest in this work. (© 2021 Viglialoro et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu